• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
PGEN

PGEN

Precigen, Inc.

NASDAQHealthcareBiotechnologyUS

USD3.81

-0.05 (-1.30%)

Rating:D+

Company Profile

CEO

Helen Sabzevari

IPO Date

2013-08-08

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$3.86

Prev. Close

$3.86

Day Low

$3.69

Day High

$3.90

52W Low

$1.30

52W High

$5.47

Market Cap

$1.14B

Volume

7.79M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

36.9%

Avg Negative

6.9%

Avg Neutral

56.3%

News Feed

Precigen Stock Surges On Positive AG019 Data for Chronic Treatment Of Type 1 Diabetes

Benzinga·6/11/2021·↑ positive

Precigen ActoBio Announces Positive Topline Results from Phase 1b/2a Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes

PRNewsWire·6/10/2021·↑ positive

Precigen to Present at the JMP Securities Life Sciences Conference

PRNewsWire·6/10/2021·↑ positive

Precigen Reports First Quarter 2021 Financial Results

PRNewsWire·5/10/2021·↑ positive

Precigen Announces Departure of Chief Financial Officer

PRNewsWire·3/30/2021·↓ negative

Precigen Announces First Patient Dosed for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)

PRNewsWire·3/23/2021·↑ positive

Precigen Receives FDA Orphan Drug Designation for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis (RRP)

PRNewsWire·3/18/2021·↑ positive

Precigen, Inc. (PGEN) CEO Helen Sabzevari on Q4 2020 Results - Earnings Call Transcript

Seeking Alpha·3/2/2021·↓ negative

Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates

Zacks Investment Research·3/1/2021·↑ positive

Will Precigen, Inc. (PGEN) Report Negative Q4 Earnings? What You Should Know

Zacks Investment Research·2/22/2021·↑ positive